Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Program
  • Investors
    • Press Releases
    • SEC Filings
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
    ►
      ◄ Back
    • Clinical Trials
    • Expanded Access Program
  • Investors
    ►
      ◄ Back
    • Press Releases
    • SEC Filings
  • Get in Touch
  • Join Us

Investors & Media

Press Releases

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Mar 30, 2020

TCR² Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Feb 18, 2020

TCR² Therapeutics to Participate in Two Upcoming Conferences in February

Feb 03, 2020

TCR² Therapeutics to Present an Allogeneic Construct at the Keystone Symposia Conference on Emerging Cellular Therapies: Cancer and Beyond

Jan 07, 2020

TCR² Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Our Science
  • Our Pipeline
  • Patients
  • Investors
  • Get in Touch
  • Join Us
  • Privacy Policy
  • Disclaimer
  • Terms of Use
  • Supply Terms

© 2023 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics